Caldwell John J, Davies Thomas G, Donald Alastair, McHardy Tatiana, Rowlands Martin G, Aherne G Wynne, Hunter Lisa K, Taylor Kevin, Ruddle Ruth, Raynaud Florence I, Verdonk Marcel, Workman Paul, Garrett Michelle D, Collins Ian
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, U.K.
J Med Chem. 2008 Apr 10;51(7):2147-57. doi: 10.1021/jm701437d. Epub 2008 Mar 18.
Fragment-based screening identified 7-azaindole as a protein kinase B inhibitor scaffold. Fragment elaboration using iterative crystallography of inhibitor-PKA-PKB chimera complexes efficiently guided improvements in the potency and selectivity of the compounds, resulting in the identification of nanomolar 6-(piperidin-1-yl)purine, 4-(piperidin-1-yl)-7-azaindole, and 4-(piperidin-1-yl)pyrrolo[2,3- d]pyrimidine inhibitors of PKBbeta with antiproliferative activity and showing pathway inhibition in cells. A divergence in the binding mode was seen between 4-aminomethylpiperidine and 4-aminopiperidine containing molecules. Selectivity for PKB vs PKA was observed with 4-aminopiperidine derivatives, and the most PKB-selective inhibitor (30-fold) showed significantly different bound conformations between PKA and PKA-PKB chimera.
基于片段的筛选确定7-氮杂吲哚为一种蛋白激酶B抑制剂骨架。利用抑制剂-PKA-PKB嵌合体复合物的迭代晶体学进行片段优化,有效地指导了化合物活性和选择性的提高,从而鉴定出具有抗增殖活性且在细胞中显示出途径抑制作用的纳摩尔级6-(哌啶-1-基)嘌呤、4-(哌啶-1-基)-7-氮杂吲哚和4-(哌啶-1-基)吡咯并[2,3-d]嘧啶PKBβ抑制剂。含4-氨基甲基哌啶和4-氨基哌啶的分子之间存在结合模式差异。4-氨基哌啶衍生物对PKB与PKA具有选择性,最具PKB选择性的抑制剂(30倍)在PKA和PKA-PKB嵌合体之间显示出显著不同的结合构象。